[1] |
Chua DT,Shan JS,Wei WJ,et al.The predictive value of the 1997 American Joint Committee on Cancer stage classification in determining failure patterns in nasopharyngeal carcinoma[J].Cancer,2001,92(11):2845-2855.
|
[2] |
高黎,易俊林,徐国镇,等.鼻咽癌根治行放疗10年经验总结[J].中华放射肿瘤学杂志,2006,15(4):249-255.
|
[3] |
顾仲义,魏青,黄克伟,等.PF方案化放疗治疗晚期鼻咽癌的远期疗效[J].中华肿瘤杂志,1997,19(5):392-393.
|
[4] |
周际昌.实用肿瘤内科学[M].北京:北京科学技术出版社,2010:444.
|
[5] |
罗宇翔.广东鼻咽癌新发病例危险因素的流行病学研究[D].广州:广州中山大学,2009.
|
[6] |
Chua MLK,Wee JTS,Hui EP,et al.Nasopharyngeal carcinoma[J].Lancet,2016,387(10022):1012-1024.
|
[7] |
Lee AWM,Ng WT,Chua LK,et al.The strength/weakness of theAJCC/UICC staging system (7thedition)for nasopharyngeal cancer and suggestions for future improvement[J].Oral Oncol,2012,48(10):1007-1013.
|
[8] |
Lee AWM,Ma BBY,Ng WT,et al.Management of nasopharyngeal carcinoma:current practice and future perpective[J].J Clin Oncol,2015,33(29):3356-3364.
|
[9] |
Chua DT,Shan JS,Kwong DL,et al.Treatment outcome after radiotherapy alone for patients with StageⅠ~Ⅱ nasophryngeal carcinoma[J].Cancer,2003,98(1):74-80.
|
[10] |
Chow E,Payne DO,Sullivan B,et al.Raduatgerapy alone in intergroup study.Is combined modality treatment really necessary?[J].Radiother Oncol,2002,63(3):269-274.
|
[10] |
高建全,鼻咽癌放化疗综合治疗进展[J].海南医学,2012,23(11):123-126.
|
[11] |
马俊,麦海强,莫浩元,等.鼻咽癌放射治疗失败原因分析[J].癌症,2000,19(11):1016-1018.
|
[12] |
王树森,管忠霞,向燕群,等.鼻咽癌组织中EGFR和PERK蛋白表达的检测及意义[J].中华肿瘤杂志,2006,28(1):28-31.
|
[13] |
廖希一,孔林,郑华,等.局部晚期鼻咽癌放了联合顺铂或尼妥珠单抗的疗效比较[J].中华放射肿瘤学杂志,2016,25(12):1277-1280.
|
[14] |
Ma BBY,Poon TCW,To KF,et al.Prognostic significance of tumor angiogenesis,Ki 67,p53 oncoprotein,epidermalgrowth factor receptor and HER2 receptor protein expressioninundifferentiatednasopharyngealcarcinoma-aprospective study[J].Head Neck,2003,25(10):864-872.
|
[15] |
石兴源,艾亮梅,黄文瑾,等.尼妥珠单抗联合顺铂同期化疗治疗局部晚期鼻咽癌疗效[J].广州医学院学报,2016,44(5):42-47.
|
[16] |
李燕巍,谢广茹,潘战宇.鼻咽癌的生物靶向治疗进展[J].临床耳鼻咽喉头颈外科杂志,2015,29(7):671-673.
|
[17] |
庄文杰,柳春晖,司徒慧如,等.老年中晚期鼻咽癌患者尼妥珠单抗联合顺铂及5-氟尿嘧啶放化疗的临床研究[J].老年医学与保健,2016,22(5):309-312.
|
[18] |
舒禹先.顺铂和5-氟脲嘧啶联合尼妥珠单抗作为一线方案治疗转移鼻咽癌的临床观察[J].实用癌症杂志,2016,31(12):2090-2092.
|